Treatment and outcome of genotype 4 chronic hepatitis C patients with pegylated interferon α-2b and ribavirin in a German real-life-setting
S Mauss, E Zehnter, MP Manns, G Teuber, T Dahhan, U Meyer, K Dach, M Bilzer, G Tossing, D Hueppe · Zeitschrift für Gastroenterologie · 2011 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Pegylated interferon (PEG-IFN) α and ribavirin (RBV) are the standard of care for hepatitis C treatment. The efficacy and safety of PEG-IFNα-2b and RBV was observed within a large German real life surveillance study. Methods: Between 9/2003 and 5/2009, a total of 279 sites (71 sites with single and dual genotype 4 patients) have treated a total of 4061 patients. 121 patients (2.9%) were infected with genotype 4. Patients with dual genotypes (genotype 4/1, 4/2, or 4/3) were excluded for the purpose of this evaluation (3/121 patients) and only patients with genotype 4 monoinfection were analyzed. Results: Th…
